Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias

Blood

Volumn 109, Issue 4, 2007, Pages 1678-1686

  Harir, Noria ^a   Pecquet, Christian ^a   Kerenyi, Marc ^b   Sonneck, Karoline ^c   Kovacic, Boris ^b   Nyga, Remy ^a   Brevet, Marie ^d   Dhennin, Isabelle ^a   Gouilleux Gruart, Valerie ^a   Beug, Hartmut ^b   Valent, Peter ^c   Lassoued, Kaiss ^a   Moriggl, Richard ^e   Gouilleux, Fabrice ^a  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT PROTEIN; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL FRACTIONATION; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME SUBUNIT; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL; LEUKEMOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

EID: 33846927933     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-029918     Document Type: Article

References (54)

1. Buitenhuis M, Coffer PJ, Koenderman L. Signal transducer and activator of transcription 5 (Stat5). Int J Biochem Cell Biol. 2004;36:2120-2124.
2. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249-259.
3. Sexl V, Piekorz R, Moriggl R, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood. 2000;96:2277-2283.
4. Kieslinger M, Woldman I, Moriggl R, et al. Anti-apoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 2000;14:232-244.
5. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98:3261-3273.
6. Bunting KD, Bradley HL, Hawley TS, et al. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood. 2002;99:479-487.
7. Cui Y, Riedlinger G, Miyoshi K, et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004;24:8037-8047.
8. Schuringa JJ, Chung KY, Morrone G, Moore MAS. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med. 2004;200:623-635.
9. Kato Y, Iwama A, Tadokoro Y, et al. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med. 2005;202:169-179.
10. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101:2940-2954.
11. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-2488.
12. Lacronique V, Boureux A, Monni R, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000;95:2076-2083.
13. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999;189:1229-1242.
14. Mizuki M, Fenski R, Halfter H. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907-3914.
15. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106:721-724.
16. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
17. Hölbl A, Kovacic B, Kerenyi M, et al. Clarifying the role of Stat5 in lymphoid development and Abelson induced transformation. Blood. 2006;107:4898-4906.
18. Ye D, Wolff N, Zhang S, Ilaria RL Jr. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood. 2006;107:4917-4925.
19. Schwaller J, Parganas E, Wang D, et al. Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Mol Cell. 2000;6:693-704.
20. Onishi M, Nosaka T, Misawa K, et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol. 1998;18:3871-3879.
21. Moriggl R, Sexl V, Kenner L, et al. Stat5 tetramer association is associated with leukemogenesis. Cancer Cell. 2005;7:87-99.
22. L gene expression by STAT5 in a bone marrow derived cell line. Oncogene. 1999;18:4191-4199.
23. Feldman GM, Rosenthal LA, Liu X, et al. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood. 1997;90:1768-1776.
24. Yoshimura A, Ichihara M, Kinjyo I, et al. Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. EMBO J. 1996;15:1055-1063.
25. Woelfle J, Billiard J, Rotwein P. Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem. 2003;278:22696-22702.
26. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999;18:4754-4765.
27. Oda A, Wakao H, Fujihara M, et al. Thrombopoietin and interleukin-2 induce association of CRK with STAT5. Biochem Biophys Res Commun. 2000;278:299-305.
28. Brockdorff JL, Gu H, Mustelin T, et al. Gab2 is phosphorylated on tyrosine upon interleukin-2/interleukin-15 stimulation in mycosis-fungoides- derived tumour T cells and associates inducibly with SHP-2 and Stat5. Exp Clin Immunogenet. 2001;18:86-95.
29. Rosa Santos SC, Dumon S, Mayeux P, Gisselbrecht S, Gouilleux F. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene. 2000;19:1164-1172.
30. Santos SC, Lacronique V, Bouchaert I, et al. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3K/Akt dependent pathway. Oncogene. 2001;20:2080-2090.
31. Nyga R, Pecquet C, Harir N, et al. Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/Map kinase pathways via the Gab2 scaffolding adapter. Biochem J. 2005;390:359-366.
32. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376:599-602.
33. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
34. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-2927.
35. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
36. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization (WHO) classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001.
37. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29:577-580.
38. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol. 2001;32:545-552.
39. Krosl J, Austin P, Beslu N, Kroon E, Humphries RK, Sauvageau G. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat Med. 2003;9:1428-1432.
40. Vocero-Akbani A, Chellaiah MA, Hruska KA, Dowdy SF. Protein transduction: delivery of Tat-GTPase fusion proteins into mammalian cells. Methods Enzymol. 2001;332:36-49.
41. Gu H, Maeda H, Moon JJ, et al. New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol Cell Biol. 2000;20:7109-7120.
42. Dijkers PF, Medema RH, Pals C, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol. 2000;20:9138-9148.
43. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol. 2000;10:1201-1204.
44. Ho JM, Nguyen MH, Dierov JK, et al. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood. 2002;100:1438-1448.
45. Nguyen MH, Ho JM, Beattie BK, Barber DL. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signalling pathway. J Biol Chem. 2001;276:32704-32713.
46. Santos SCR, Monni R, Bouchaert I, et al. Involvement of the NF-κB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Lett. 2001;497:148-152.
47. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI3-K /Akt-dependent pathway. EMBO J. 1997;16:6151-6161.
48. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signalling circuit. J Cell Biol. 2004;167:197-201.
49. Nishida K, Hirano T. The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci. 2003;94:1029-1033.
50. Sattler M, Mohi MG, Pride YB, et al. Role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002;1:479-492.
51. Scherr M, Chaturvedi A, Battmer K, Dallmann I, et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood. 2005;107:3279-3287.
52. Verdier F, Rabionet R, Gouilleux F, et al. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B. Mol Cell Biol. 1998;18:5852-8560.
53. John S, Vinkemeier U, Soldaini E, Darnell JE Jr, Leonard WJ. The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol. 1999;19:1910-1918.
54. Meyer WK, Reichenbach P, Schindler U, Soldaini E, Nabholz M. Interaction of STAT5 dimers on two low affinity binding sites mediates interleukin 2 (IL-2) stimulation of IL-2 receptor alpha gene transcription. J Biol Chem. 1997;272:31821-31828.